KRAS and neoplasm: The in vitro results prompted us to test the effect of alisertib and trametinib combination in vivo. Mutant KRAS tumours were treated for 14 days (H2009) or until control tumours reached the largest volume allowed under the ethical protocol (11 days, H1792).